Testing in Patients with Known HSV Exposure
In patients with known exposure to HSV, testing should be performed using nucleic acid amplification tests (NAATs) such as PCR from active lesions if present, or type-specific serologic testing (HSV-2 glycoprotein G antibody testing) if asymptomatic, with serology delayed until at least 12 weeks post-exposure to avoid false-negative results during the window period. 1
Testing Strategy Based on Clinical Presentation
If Active Lesions Are Present
NAAT/PCR is the test of choice for symptomatic patients with active mucocutaneous lesions, as it demonstrates 11-71% superior detection rates compared to viral culture 2. This approach prioritizes accurate diagnosis to guide appropriate antiviral therapy and reduce transmission risk.
Specimen collection technique matters significantly:
- Open vesicles with a sterile needle and collect vesicular fluid with a swab 2
- For ulcerative lesions, sample the base of the ulcer or burst vesicle using a Kimura scraper or swab 2
- Collect urethral specimens by inserting swab 0.5-2 cm into the urethral meatus in males, 0.5 cm in females 2
- For cervical lesions, insert swab 2 cm into the cervical canal after cleaning the os 2
Alternative testing if NAAT unavailable:
- Antigen detection via enzyme immunoassay (EIA) has ≥95% sensitivity for symptomatic patients 2
- Viral culture remains acceptable but has lower sensitivity, particularly for ulcerative (70%) versus vesicular (>90%) lesions 2
If Asymptomatic After Known Exposure
Type-specific HSV-2 serology is indicated for patients with known exposure but no active lesions 2, 1. This is critical for determining if infection was acquired and guiding counseling about transmission risk.
Critical timing consideration: Wait at least 12 weeks after exposure before testing, as the serologic window period can extend up to 12 weeks, and testing earlier will yield false-negative results 1.
Important Caveats About Serologic Testing
HSV-2 serologic assays have significant limitations that must be understood before ordering:
- Low index values (1.1-2.9) have only 39.8% specificity, meaning high false-positive rates 1
- Index values ≥3.0 have 78.6% specificity and may be sufficient for diagnosis without confirmation 1
- Patients with HSV-1 infection are more likely to have false-positive HSV-2 results with low index values 1
Confirmation strategy for low-positive results:
- Index values <3.0 should ideally be confirmed with a second assay using different glycoprotein G antigen (e.g., Biokit HSV-2 rapid assay) or Western blot 1
- This improves positive predictive value from 80.5% to 95.6% 1
HSV-1 serology has poor sensitivity (70.2%) and frequently yields false-negative results, limiting its clinical utility 1
Who Should Be Tested
According to guidelines, testing is specifically recommended for 2:
- Persons with sexual contact with a proven HSV case (your scenario)
- Those being examined for other sexually transmitted infections
- Pregnant women at risk of acquiring HSV near delivery
- HIV-positive individuals
- Men who have sex with men
- Partners in HSV-discordant couples
Common Pitfalls to Avoid
Do not test serologically before 12 weeks post-exposure - you will get false negatives during the window period 1
Do not accept low-positive HSV-2 serology results (index <3.0) without confirmation - the false-positive rate is unacceptably high, particularly in those with HSV-1 infection 1
Do not rely on clinical diagnosis alone - clinical differentiation from other causes of genital ulceration (syphilis, chancroid, Behçet syndrome, Crohn disease) is unreliable 2
Do not use IgM testing to determine acute infection - approximately one-third of patients with recurrent HSV-2 have IgM responses, making it a poor indicator of recent infection 2
Avoid delayed or unrefrigerated transport of specimens for culture - this substantially reduces detection rates 2
Clinical Significance
Accurate HSV diagnosis impacts long-term sexual health, partner counseling, pregnancy management, and antiviral therapy decisions 1. Type differentiation between HSV-1 and HSV-2 is essential because genital HSV-2 has much higher recurrence rates and subclinical shedding compared to genital HSV-1 2, 1.